(PDF) P054 Applicability of the Lung-molGPA Index in NSCLC

P054 Applicability of the Lung-molGPA Index in NSCLC Patients With Different Gene Alterations and Brain Metastases

Journal of Thoracic Oncology - United States

doi 10.1016/j.jtho.2018.10.076

Full Text

Abstract

Available in full text

Categories

Respiratory Medicine

Date

December 1, 2018

Authors

Publisher

Elsevier BV

Related search

P2.01-30 Applicability of Lung-molGPA Index in Non-Small Cell Lung Cancer Patients With Different Gene Alterations and Brain Metastases

Journal of Thoracic Oncology

Respiratory Medicine

English

P2.01-127 Efficacy of Endostar Combined With Whole Brain Radiotherapy in Patients With NSCLC Brain Metastases

Journal of Thoracic Oncology

Respiratory Medicine

English

P044 Cost-Effectiveness Analysis of Icotinib vs Whole-Brain Irradiation in NSCLC Patients With Brain Metastases

Journal of Thoracic Oncology

Respiratory Medicine

English

MA08.06 Outcomes Among Patients With EGFR-Mutant Metastatic NSCLC With and Without Brain Metastases

Journal of Thoracic Oncology

Respiratory Medicine

English

Efficacy and Safety of Icotinib in Patients With Brain Metastases From Lung Adenocarcinoma

OncoTargets and Therapy

English

P3.01-79 Intracerebral Efficacy of Immune Check-Point Inhibitors in NSCLC Patients With Brain Metastases

Journal of Thoracic Oncology

Respiratory Medicine

English

Survival of Patients With Non-Small Cell Lung Cancer and Brain Metastases

Clinical Oncology

Nuclear Medicine

English

Cost Analysis of the Management of Brain Metastases in Patients With Advanced ALK+ NSCLC: Alectinib Versus Crizotinib

Lung Cancer Management

English

MA08.09 Impact of Brain Metastases in Immune Checkpoint Inhibitors (ICI) Treated Advanced Non-Small Cell Lung Cancer (NSCLC) Patients

Journal of Thoracic Oncology

Respiratory Medicine

English